Creative Diagnostics Announces New Insect Nucleic Acid Residue Assay Kits for Enhanced Quality Control

January 17, 2025 05:20 PM AEDT | By EIN Presswire
 Creative Diagnostics Announces New Insect Nucleic Acid Residue Assay Kits for Enhanced Quality Control
Image source: EIN Presswire

Creative Diagnostics has announced the launch of its new Insect Nucleic Acid Residue Assay Kits based on quantitative fluorescence PCR technology.

NEW YORK, NY, UNITED STATES, January 17, 2025 /EINPresswire.com/ -- Creative Diagnostics, a reagent supplier and developer focused on biologics quality control, has announced the launch of its new Insect Nucleic Acid Residue Assay Kits based on quantitative fluorescence PCR technology. These kits are designed for highly sensitive and specific detection of insect DNA residues, ensuring the quality and safety of biopharmaceuticals, research products, and other biological materials.

Creative Diagnostics is dedicated to providing researchers with nucleic acid residue assay kits that help manufacturers detect, quantify and control residual host cell DNA, viral vector nucleic acids, recombinant DNA and foreign nucleic acids to ensure the safety, purity and consistency of the final product. By incorporating nucleic acid testing into the quality control process, biopharmaceutical companies can improve the quality and compliance of their products and ultimately protect public health.

The presence of insect DNA can be a significant problem in a variety of industries, particularly biologics manufacturing and food processing. Creative Diagnostics' new Insect Nucleic Acid Residue Assay Kits address this critical need by providing a reliable, efficient method for detecting even trace amounts of insect DNA. These kits use quantitative polymerase chain reaction (qPCR) technology, which provides high sensitivity and specificity for accurate quantification of insect nucleic acid residues. This precision is essential to meet stringent quality control standards and regulatory requirements.

For example, the Sf9 DNA Fragment Residue Assay Kit (Cat. No. DDNA-035) is designed to quantitatively analyze and detect the size distribution of residual Sf9 DNA fragments in a wide range of biological products, including intermediates, semi-finished and finished products. The kit is developed for four different amplification fragments (87 bp, 118 bp, 225 bp, 500 bp) using the PCR fluorescent probe assay principle and is equipped with a reference standard for quantification of Sf9 DNA. This kit is used in conjunction with the Creative Diagnostics Host Cell DNA Pre-treatment Kit.

The ResDetFast™ Hi5 & AcNPV DNA Residue Assay Kit (Cat. No. DDNAF-033) uses the PCR fluorescent probe method to design primers targeting the conserved genes of Hi5 cells and AcNPV, respectively, which can quantitatively detect the residual DNA of Hi5 cells and AcNPV in the genetically engineered vaccines produced by the insect cell-barcovirus expression system. The kit contains an internal standard to monitor abnormal extraction and amplification and to prevent false negatives.

Creative Diagnostics' mission is to provide cutting-edge tools and solutions for the advancement of scientific research and the improvement of human health. These new Insect Nucleic Acid Residue Assay Kits provide an important tool for ensuring product quality and safety in a variety of industries. For more information on the new assay kits, please visit https://qbd.creative-diagnostics.com/products/insect-nucleic-acid-residue-assay-kits-qpcr-2794.html.

About Creative Diagnostics

Creative Diagnostics is a global leader in the development and manufacturing of innovative tools and reagents for bioprocess impurity analysis. The company offers a comprehensive portfolio of solutions to support researchers in the quality control of biologics and provides biopharmaceutical quality, purity and safety assays, analytical methods and applications for the biotechnology and biopharmaceutical industries.

Thomas Schmitt
Creative Diagnostics
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.